title: Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP).
abstract: A program designed to increase the percentage of patients at a Department of Veterans Affairs health system who meet their cholesterol goals as recommended by the National Cholesterol Education Program (NCEP) is described, and baseline results are reported. Patients with an active prescription for pravastatin between February 4 and June 4, 1997, were identified for conversion to simvastatin by means of the Pravastatin-to-Simvastatin Conversion Lipid-Optimization Program; 1361 patients were eligible for conversion. Each patient was mailed a survey for determining risk factors for coronary heart disease (CHD) and NCEP-recommended low-density lipoprotein (LDL) cholesterol goal and was asked to provide a fasting blood sample for determination of lipid profile, liver function, and serum creatine phosphokinase concentration. The patients were asked to make a follow-up laboratory visit six to seven weeks after they had started taking simvastatin. The percentage change from baseline and the percentage of patients who meet their LDL cholesterol goal before and after the conversion will be determined. A total of 1115 patients were converted to simvastatin. Only 35.4% of patients taking pravastatin to prevent a second CHD-related event met or exceeded their LDL cholesterol goal. Only 36.2% of patients with two or more CHD risk factors who were taking pravastatin for primary prevention met or exceeded their LDL cholesterol goal. In a veterans population, less than half of patients receiving a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor had LDL cholesterol concentrations that met goals recommended by the NCEP.
authors.affiliation: School of Pharmacy, University of the Pacific, Stockton, CA, USA.
authors.forename: M K
authors.initials: MK
authors.lastname: Ito
authors.forename: S N
authors.initials: SN
authors.lastname: Stolley
authors.forename: A P
authors.initials: AP
authors.lastname: Morreale
authors.forename: J C
authors.initials: JC
authors.lastname: Lin
authors.forename: D B
authors.initials: DB
authors.lastname: Marcus
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D002140:California; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control*; D004334:Drug Administration Schedule; D005260:Female; D006285:Health Planning; D006787:Hospitals, Veterans; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010607:Pharmacy Service, Hospital; D017035:Pravastatin / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D019821:Simvastatin; D017035:Pravastatin